Movement Alert｜CANSINOBIO Rises 7.93% in Regular Trading, CLSA Maintains Outperform Rating with 56% Upside Potential

Market Focus09-02 09:36

On September 2, CANSINOBIO rose 7.93% in regular trading, trading at HK$31.38/share, with turnover of HK$77.42 million. The rebound followed CLSA's latest research report maintaining an Outperform rating on the company with a target price of HK$49.6, implying approximately 56% upside from current levels.

CLSA raised its net profit forecasts for the company to RMB 121 million, RMB 323 million, and RMB 723 million respectively, citing growth momentum from its recently approved tetanus vaccine. The stock had pulled back over several consecutive trading sessions since August 27 on profit-taking pressure after a strong rally driven by multiple catalysts, including Moderna's positive Phase III mRNA cancer vaccine data, an mRNA tumor vaccine collaboration with deepGeneAI, and the tetanus vaccine NDA approval on August 20.

The company's H1 results showed revenue of RMB 550 million, up 43.81% year-over-year, with net losses narrowing 94.65% to just RMB 720,000. Overseas revenue reached approximately RMB 152 million, achieving significant growth. The company is scheduled to hold an online interim results briefing on September 3.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145887340?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-02 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145887340","market":"hk","top_or_hot":-1,"title":"Movement Alert｜CANSINOBIO Rises 7.93% in Regular Trading, CLSA Maintains Outperform Rating with 56% Upside Potential","media":"Market Focus","content":"<p><p>On September 2, CANSINOBIO rose 7.93% in regular trading, trading at HK$31.38/share, with turnover of HK$77.42 million. The rebound followed CLSA's latest research report maintaining an Outperform rating on the company with a target price of HK$49.6, implying approximately 56% upside from current levels.</p><p>CLSA raised its net profit forecasts for the company to RMB 121 million, RMB 323 million, and RMB 723 million respectively, citing growth momentum from its recently approved tetanus vaccine. The stock had pulled back over several consecutive trading sessions since August 27 on profit-taking pressure after a strong rally driven by multiple catalysts, including Moderna's positive Phase III mRNA cancer vaccine data, an mRNA tumor vaccine collaboration with deepGeneAI, and the tetanus vaccine NDA approval on August 20.</p><p>The company's H1 results showed revenue of RMB 550 million, up 43.81% year-over-year, with net losses narrowing 94.65% to just RMB 720,000. Overseas revenue reached approximately RMB 152 million, achieving significant growth. The company is scheduled to hold an online interim results briefing on September 3.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CANSINOBIO Rises 7.93% in Regular Trading, CLSA Maintains Outperform Rating with 56% Upside Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CANSINOBIO Rises 7.93% in Regular Trading, CLSA Maintains Outperform Rating with 56% Upside Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-02 09:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 2, CANSINOBIO rose 7.93% in regular trading, trading at HK$31.38/share, with turnover of HK$77.42 million. The rebound followed CLSA's latest research report maintaining an Outperform rating on the company with a target price of HK$49.6, implying approximately 56% upside from current levels.</p><p>CLSA raised its net profit forecasts for the company to RMB 121 million, RMB 323 million, and RMB 723 million respectively, citing growth momentum from its recently approved tetanus vaccine. The stock had pulled back over several consecutive trading sessions since August 27 on profit-taking pressure after a strong rally driven by multiple catalysts, including Moderna's positive Phase III mRNA cancer vaccine data, an mRNA tumor vaccine collaboration with deepGeneAI, and the tetanus vaccine NDA approval on August 20.</p><p>The company's H1 results showed revenue of RMB 550 million, up 43.81% year-over-year, with net losses narrowing 94.65% to just RMB 720,000. Overseas revenue reached approximately RMB 152 million, achieving significant growth. The company is scheduled to hold an online interim results briefing on September 3.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1145887340","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145887340","pubTimestamp":1788312965,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 2, CANSINOBIO rose 7.93% in regular trading, trading at HK$31.38/share, with turnover of HK$77.42 million. The rebound followed CLSA's latest research report maintaining an Outperform...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"走势提醒|康希诺生物常规交易上涨7.93%，里昂证券维持跑赢大盘评级，上涨潜力56%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"On September 2, CANSINOBIO rose 7.93% in regular trading, trading at HK$31.38/share, with turnover of HK$77.42 million. The rebound followed CLSA's latest research report maintaining an Outperform rating on the company with a target price of HK$49.6, implying approximately 56% upside from current levels.CLSA raised its net profit forecasts for the company to RMB 121 million, RMB 323 million, and RMB 723 million respectively, citing growth momentum from its recently approved tetanus vaccine. The stock had pulled back over several consecutive trading sessions since August 27 on profit-taking pressure after a strong rally driven by multiple catalysts, including Moderna's positive Phase III mRNA cancer vaccine data, an mRNA tumor vaccine collaboration with deepGeneAI, and the tetanus vaccine NDA approval on August 20.The company's H1 results showed revenue of RMB 550 million, up 43.81% year-over-year, with net losses narrowing 94.65% to just RMB 720,000. Overseas revenue reached approximately RMB 152 million, achieving significant growth. The company is scheduled to hold an online interim results briefing on September 3.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145887340","isCrawlerRequest":true}